STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +55

Reasons to Add STE Stock to Your Portfolio Right Now

Company update AI-generated analysis

πŸ“ˆ STERIS Healthcare segment revenues rose 8% to $1.05 billion in Q1 fiscal 2027, driven by 9% growth in consumables and 10% growth in services.

πŸ’° The company expanded its Healthcare EBIT margin by 60 basis points to 24.8%, supported by favorable mix and productivity gains.

πŸ“¦ Capital equipment backlog increased to $444 million, reflecting strong order intake despite shipment timing variations.

πŸ”¬ AST segment revenues grew 6% to $297.6 million in Q1 fiscal 2027, with services up 11% and operating profit above $500 million for the year.

🏭 STERIS announced a $600 million investment in a new formulated chemistries Center of Excellence in North Carolina to boost manufacturing capacity.

πŸ“‰ Shares lost 8.3% over the past year, underperforming the industry's 7.7% growth and the S&P 500's 16.6% rise during the same period.

⚠️ Gross tariff costs reached $14 million in Q1 fiscal 2027, though partially offset by $4 million in refunds, with management warning of persistent cost pressures.

πŸ“Š The company holds a Zacks Rank #2 (Buy) and has delivered an average earnings surprise of 1.18% over the trailing four quarters.

Bullish Signals
  • STERIS Healthcare segment revenues rose 8% to $1.05 billion in Q1 fiscal 2027, driven by strong growth in consumables and services.
  • The company expanded its Healthcare EBIT margin by 60 basis points to 24.8%, supported by higher volumes and pricing power.
  • Capital equipment backlog rose to $444 million, indicating robust demand for STERIS' capital equipment offerings.
  • AST segment generated over $1 billion in revenues in fiscal 2026 with operating profit exceeding $500 million.
  • STERIS announced a $600 million investment in a new formulated chemistries Center of Excellence in North Carolina, projected to generate more than $700 million in revenues.
Risk Factors
  • Shares lost 8.3% over the past year, significantly underperforming the industry's 7.7% growth and the S&P 500's 16.6% rise.
  • Inflation partly offset pricing and productivity gains in the Healthcare and Life Sciences segments, limiting further margin expansion.
Full Analysis
STERIS plc's STE Healthcare segment is demonstrating strong market adoption with significant revenue growth in the first quarter of fiscal 2027. Healthcare revenues rose 8% to $1.05 billion, driven by a 9% increase in consumables and a 10% rise in services, while capital equipment orders grew 4%. The segment achieved an EBIT margin expansion of 60 basis points to 24.8%, supported by higher volumes and pricing power, though partially offset by inflation and tariffs. The Applied Sterilization Technologies (AST) segment continues to generate robust service revenues, reaching over $1 billion in fiscal 2026 with operating profits exceeding $500 million. In the first quarter of fiscal 2027, AST revenues increased 6% to $297.6 million, fueled by an 11% growth in services. While customers are currently reducing inventories following difficult prior-year comparisons, destocking is expected to ease in the second half of the year, promising improved growth prospects. STERIS is expanding its operational footprint with a new $600 million formulated chemistries Center of Excellence in North Carolina, which will combine manufacturing, R&D, and distribution for Healthcare and Life Sciences products. This strategic investment is projected to generate more than $700 million in revenues. The company maintains a market capitalization of $21.18 billion and has delivered an average earnings surprise of 1.18% over the trailing four quarters.